Gastric Device Market Size, Share & Trends Analysis | Global | 2026-2032 | Includes: Gastric Bands and Gastric Balloons

Global Gastric Device Market Report to 2032

The global gastric device market was valued at over $124 million in 2025. It is expected to grow modestly at a compound annual growth rate (CAGR) of approximately 1.1%, reaching approximately $134 million by 2032.

This comprehensive report covers the global market for gastric devices, including gastric balloons and gastric bands. Gastric bands now represent a very small and declining portion of the market.

The analysis includes unit sales, average selling prices (ASPs), market size, growth trends, market drivers and limiters, market forecasts through 2032, and historical data back to 2022. It also includes recent mergers and acquisitions, company profiles, product portfolios and leading competitors.

Growth in this market is limited by strong competition from bariatric surgery and the rapid adoption of GLP-1 receptor agonist medications. Gastric devices are increasingly positioned as temporary, reversible or bridge therapies rather than definitive obesity treatments.

Market Overview

The global gastric device market includes devices used to support weight-loss interventions, primarily gastric balloons and gastric bands. These devices are designed to help patients lose weight through temporary gastric volume reduction or anatomical restriction.

Gastric balloons represent the more relevant segment of the market today. They are typically positioned as less invasive, temporary and reversible options for patients who are unwilling to undergo surgery or who may not qualify for more invasive bariatric procedures.

Gastric bands have declined significantly. Even adjustable band systems, including legacy LAP-BAND(R) platforms, have experienced sustained contraction due to long-term complication rates, revision procedures and shifting surgeon preference toward other bariatric techniques.

Since 2023, GLP-1 receptor agonist medications have materially impacted the gastric device market. In the U.S. in particular, balloon procedure volumes declined significantly in 2023 as pharmacologic weight-loss therapies gained mainstream adoption. While long-term adherence and durability remain under evaluation, their short-term effect on interventional weight-loss procedures has been substantial.

Market Drivers

Increasing obesity rates continue to support long-term demand for weight-loss interventions. Morbid obesity is commonly defined as a BMI over 40, or over 35 with obesity-related comorbidities such as type 2 diabetes or hypertension. This growing patient population sustains the broader bariatric treatment ecosystem.

However, the direct impact of obesity prevalence on gastric devices is limited. Gastric balloons and bands serve a more selective patient group than bariatric surgery or pharmacologic therapies. Demand is strongest among patients seeking non-surgical, temporary or reversible treatment options.

New developments and market repositioning are also shaping the gastric device market. As gastric banding and balloon procedures have declined over time, manufacturers have repositioned gastric devices as adjunctive or bridge therapies rather than permanent solutions. Product development is increasingly focused on less invasive systems that support selected patient needs while reducing procedural burden and anatomical alteration.

Market Limiters

Bariatric surgery remains the strongest limiter for the gastric device market. Procedures such as sleeve gastrectomy and gastric bypass offer more durable weight-loss outcomes and are supported by well-established clinical evidence. As a result, surgical approaches have become the preferred standard of care for many patients with severe obesity.

Robotic-assisted bariatric surgery further reinforces this shift. Robotic platforms improve surgeon ergonomics, visualization and precision in complex bariatric procedures. This strengthens the surgical value proposition and makes surgery more attractive in settings where hospitals have access to robotic platforms.

GLP-1 receptor agonist medications have also become a major limiter. Since 2023, these drugs have reduced demand for some interventional weight-loss procedures, especially gastric balloon procedures in the U.S. Even though long-term adherence, cost and durability are still being evaluated, their near-term impact has been strong enough to materially pressure the gastric device market.

Market Coverage and Data Scope

• Quantitative coverage: Market size, market shares, market forecasts, market growth rates, units sold and average selling prices.
• Qualitative coverage: Market drivers and limiters, market size and growth trends, recent mergers and acquisitions, company profiles, product portfolios and leading competitors.
• Time frame: Base year 2025, forecasts to 2032, and historical data back to 2022.
• Data types included: Unit sales, average selling prices, market size and growth trends, market drivers and limiters, market forecasts through 2032, historical data, recent mergers and acquisitions, company profiles and product portfolios.
• Method note: Market revenue is modeled using unit sales and average selling prices, with segmentation by device type used to assess demand across gastric bands and gastric balloons.

The report is designed to help readers evaluate how obesity prevalence, GLP-1 adoption, bariatric surgery, robotic-assisted procedures and product repositioning are shaping the global gastric device market.

Markets Covered and Segmentation

Gastric Device Market

• Device type: Gastric band and gastric balloon.

Gastric bands include adjustable banding systems used to restrict stomach capacity. This segment now represents a small and declining portion of the total gastric device market.

Gastric balloons include temporary, space-occupying devices intended to support short-term weight loss, often in combination with lifestyle intervention or broader obesity management programs.

Each segment is analyzed through relevant quantitative measures, including market size, market shares, market forecasts, market growth rates, units sold and average selling prices.

Competitive Analysis

Allurion Technologies is a key competitor in the global gastric balloon market. The company offers the Allurion(R) Balloon system, a swallowable, procedure-light weight-loss solution designed to avoid endoscopy for placement and removal. The platform is positioned as a minimally invasive and reversible alternative to both surgical bariatric procedures and traditional endoscopic balloons.

In February 2026, Allurion received U.S. FDA premarket approval for its gastric balloon system for short-term weight loss in combination with lifestyle intervention. This marked its formal entry into the U.S. market and significantly expanded the company's commercial footprint. This regulatory milestone strengthens Allurion's positioning within the North American gastric device segment.

Boston Scientific maintained a notable presence in the gastric device segment following the integration of Apollo Endosurgery into its portfolio. The company's position is supported by endoluminal and bariatric-adjacent technologies, including the OverStitch(TM) endoscopic suturing system, which complements its broader minimally invasive and gastrointestinal surgery franchise.

Medtimo, formerly ReShape Lifesciences, remained a niche competitor in 2025, primarily associated with the legacy LAP-BAND(R) adjustable gastric banding system. While the company continues to pursue additional obesity treatment technologies, including balloon-based solutions, these products had not yet materially contributed to market revenue as of 2025.

Technology and Practice Trends

Gastric balloons are increasingly positioned as temporary and reversible obesity treatment options. This positioning is important as the market shifts away from permanent or anatomy-altering devices.

Swallowable balloon systems are an important area of development. Products designed to reduce or avoid endoscopy may lower procedural burden and appeal to patients seeking less invasive treatment options.

Gastric bands continue to decline as clinical preference shifts toward sleeve gastrectomy, gastric bypass and other bariatric approaches. Long-term complication rates and revision procedures have reduced surgeon and patient interest in banding.

GLP-1 medications are reshaping the obesity treatment pathway. Their rapid adoption has created a new standard of comparison for non-surgical weight-loss interventions, placing pressure on gastric device manufacturers to prove value in patient groups where medication adherence, cost or eligibility may be challenging.

Robotic-assisted bariatric surgery is strengthening the appeal of surgical treatment. As surgical workflows become more precise and standardized, gastric devices face greater pressure from procedures that offer more durable outcomes.

Manufacturers are increasingly repositioning gastric devices as adjunctive or bridge therapies. This may include use in patients who are not ready for surgery, are not surgical candidates or require temporary weight reduction before a more definitive intervention.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Why This Report

How large is the global gastric device market, and how is it expected to grow through 2032?

How are gastric balloons and gastric bands performing across global obesity treatment markets?

How are unit sales, average selling prices and market values changing over time?

Why have gastric bands become a small and declining portion of the market?

How has GLP-1 medication adoption affected gastric balloon procedure volumes?

What role do gastric devices still play as temporary, reversible or bridge therapies?

How are bariatric surgery and robotic-assisted bariatric procedures limiting market growth?

Which companies are active in the gastric device market, and how are Allurion Technologies, Boston Scientific and Medtimo positioned?

The Global Gastric Device Market Report from iData Research answers these questions with detailed market sizing, ASP trends, forecasts and competitive share insights. Use it to evaluate demand, benchmark competitors, assess the impact of GLP-1 therapies and plan for growth across the global gastric device market.